Monoclonal Antibody for Inhibition of Angiogenesis and Tumor Growth

Description:

Inventors have generated a monoclonal antibody to TRAF3IP3 that inhibits tumor growth. Inventors discovered that TRAF3IP3 is overexpressed in malignant tumor blood vessels, as well as a panel of tumor cell lines. TRAF3IP3 silenced in angiosarcoma, osteosarcoma, and melanoma inhibit proliferation and increase apoptosis. In vivo, TRAF3IP3 silenced in melanoma inhibits tumor growth by 83% and angiosarcoma growth by 38%. These antibodies block tumor growth and induce apoptosis in in vivo models of melanoma and other cancers. They work by blocking JNK signal transduction pathways that are critical for tumor growth, invasion, angiogenesis and metastasis. The antibodies may also be useful for in vivo imaging of TRAF3IP3 positive tumors and/or for tissue diagnosis and prognosis.

 

TRAF3IP3 protein is present in melanoma and malignant endothelial cells, and silencing TRAF3IP3 in malignant endothelial cells inhibits angiogenesis in vitro and in vivo. Further, silencing TRAF3IP3 in melanoma cells reduces proliferation and increases apoptosis in vitro, and reduces melanoma xenograft growth in vivo by 83%. TRAF3IP3 is required for melanoma growth and angiogenesis and therefore is a novel therapeutic target.

 

Overview:

The worldwide incidence of melanoma has increased over the past few decades, with more than 132,000 people diagnosed with the disease every year. In the United States,

5 nearly 9,500 individuals will die of melanoma in 2013. Surgery has been the mainstay of treatment for localized disease. However, despite adequate surgery and approved adjuvant treatments, recurrence rates remain high for stage III disease, with relapse-free survival rates of

63%, 32%, and 11% for stages IIIA, IIIB, and IIIC, respectively. The prognosis for patients with stage IV disease is poor, with a historical median survival of approximately 9 months

 

Applications: Inhibition of tumor growth. Inhibition of angiogenesis dependent diseases such as tumors, macular degeneration, arthritis, and endometriosis. Use as an immunosuppressant. Melanoma, osteosarcoma, angiosarcoma, breast cancer, gastric cancer, glioblastoma, lymphoma, plasmocytoma, or other cancers that express TRAF3IP3.

Advantages: Inhibits tumor growth

Key Words: Monclonal antibody, tumor, angiosarcoma, melanoma, apoptosis, cancer, malignant

 

Inventors: Nancy DeMore

Patent Status: Provisional Application Filed 02/22/2016

MUSC-FRD Technology ID: P1530

 

Patent Information:
Category(s):
Therapeutic
For Information, Contact:
Chelsea Ex-Lubeskie
Licensing Manager, Devices
MUSC Foundation for Research Development
843-876-1900
exlubesk@musc.edu
Inventors:
Nancy DeMore
Keywords:
© 2017. All Rights Reserved. Powered by Inteum